BAC B.V. Affinity Ligand Licensed for Clinical and Commercial Scale-up of LFB Biotechnologies' Recombinant Factor VIIa

NAARDEN, Netherlands--(BUSINESS WIRE)--BAC BV, the leading provider of antibody-based affinity purification technology, has announced that it has extended its license agreement with LFB Biotechnologies (Les Ulis, France), to cover the use of BAC’s anti-Factor VIIa CaptureSelect® affinity ligand in the large-scale purification of recombinant human Factor VIIa (rhFVIIa). LFB Biotechnologies, a biopharmaceutical company working in the highly specialized field of plasma-derived medicinal and biotech products, began working with BAC in May 2008 to develop a custom-designed affinity ligand for the purification of the rhFVIIa product that it developed in partnership with GTC Biotherapeutics (Nasdaq:GTCB).

Back to news